Business Context and Reporting Period
This Form 8-K filing by Fluidigm Corporation (not Standard BioTools Inc.) was submitted on February 10, 2017, reporting events occurring on February 6, 2017. The filing addresses Item 5.02 regarding the approval of a retention compensation program for key executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
Material Changes
The Board of Directors approved a retention program for the CEO, CFO, and other Section 16 officers. The program includes:
- A lump sum cash payment contingent on employment through January 1, 2019.
- Grants of stock options and restricted stock units (RSUs) under the 2011 Equity Incentive Plan.
- The CEO, S. Christopher Linthwaite, elected to receive equity awards in lieu of the cash component.
Executive Retention Awards
| Officer | Role | Cash Award | Stock Options | RSUs |
|---|---|---|---|---|
| S. Christopher Linthwaite | CEO | $0 | 189,500 | 76,000 |
| Vikram Jog | CFO | $138,400 | 87,400 | 34,600 |
| Steven C. McPhail | CCO | $102,800 | 51,375 | 20,550 |
| Mai-Chan (Grace) Yow | EVP, Manufacturing | $76,300 | 48,400 | 19,500 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. The primary contingency noted is that cash awards are conditional upon the executive remaining employed through January 1, 2019. Equity awards are subject to standard vesting terms and the 2011 Equity Incentive Plan.
Investor Verification Checklist
- Verify the total dilution impact of the 376,675 stock options and 150,650 RSUs granted.
- Confirm the specific vesting schedule details referenced in the 2011 Equity Incentive Plan.
- Review the Form of Award Agreement (Exhibit 10.1) for specific forfeiture conditions.
- Note that the filing entity is Fluidigm Corporation, not Standard BioTools Inc.